Roughly 45% of seniors enrolled in standalone Medicare drug plans could watch their monthly premium climb by more than $10 in 2027, the direct result of a federal subsidy the government has now decided to let expire. The Centers for Medicare & Medicaid Services confirmed on July 28 that the Part D Premium Stabilization Demonstration will end after the 2026 plan year, returning standalone drug coverage to ordinary market pricing. The increase will not land evenly, and how much any one enrollee pays turns almost entirely on the specific plan carried into next year.
What the Part D stabilization subsidy did before it lapsed
The demonstration began in 2025 as a voluntary program for standalone prescription drug plans, built to soften the premium swings that followed the Inflation Reduction Act’s redesign of the Part D benefit. That redesign capped out-of-pocket drug spending and reshuffled who pays for catastrophic costs, changes that left plan actuaries guessing at their real exposure. Under the demonstration, the federal government quietly absorbed part of each participating plan’s costs, letting advertised premiums stay lower than the underlying arithmetic would otherwise allow.
The support did not come cheap. The Government Accountability Office estimated the arrangement would cost about $9.8 billion across 2025 and 2026, a price tag that fueled criticism as its full scope came into view. Backers framed it as a temporary bridge while plans learned the new benefit; skeptics called it a bailout that masked the true cost of coverage and delayed a reckoning that would only grow larger with time.
CMS now says the props are no longer necessary. In releasing its 2027 technical bid information, the agency concluded that standalone drug plans have gathered enough experience with the redesigned benefit to price coverage on their own. The same release set the 2027 national average monthly bid at $296.05, roughly 24% above the $239.27 figure a year earlier, and fixed the base beneficiary premium at $41.33 under the law’s 6% annual growth cap.
Free retirement updates: Social Security and Medicare change every year, and nobody sends a memo. The free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Which enrollees land in the 45% and which see no change
The coming increase is anything but uniform. A Wall Street Journal analysis of the transition projected that about 25% of standalone drug-plan enrollees will see no premium change at all, roughly 30% will pay less than $10 more a month, and about 45% will face an increase larger than $10. The demonstration reached a large slice of the roughly 25 million people who hold standalone Part D coverage, so even a partial withdrawal ripples across millions of fixed-income household budgets.
Health-policy researchers have pushed back on the most sweeping headlines. KFF, reviewing the same decision, noted that some beneficiaries could face larger premium increases next year while others may actually see lower premiums as the market resets. The enrollees most exposed tend to sit in plans that leaned hardest on the subsidy to advertise a rock-bottom price, and those are precisely the plans with the most room to correct upward.
Members of Medicare Advantage plans that fold drug coverage into a single premium sit outside this particular shift, since the demonstration applied only to standalone prescription drug plans. That distinction will shape how the 2027 numbers are read. A premium jump concentrated in standalone plans can quietly nudge some retirees toward a bundled option, which reshuffles the calculus of doctors, pharmacies and formularies that standalone coverage otherwise leaves untouched.
How the fall premium notices tie into the enrollment decision
Every plan must mail an Annual Notice of Change before the fall, spelling out the next year’s premium, deductible and covered drugs. Those notices are the first place the end of the subsidy will show up in plain figures, and they arrive just before the one stretch of the year when coverage can be swapped. Reading the notice line by line, rather than tossing it, is what separates an enrollee who absorbs a silent increase from one who acts on it.
The Medicare open enrollment window running October 15 through December 7 is the stretch to change or drop a drug plan, with any switch taking effect January 1. Comparing plans during that window matters more in a year when premiums are moving, because a person locked into a plan that raises its price sharply has no easy exit until the following autumn.
The larger question is whether the redesigned Part D benefit can stand without support once the cushion comes out. CMS is betting that plans have learned to price the benefit accurately after two years of real claims data and that competition will hold increases down. Enrollees get the verdict in their fall notices, and the gap between a plan that spikes and one that holds steady may be the single number worth checking before the December deadline arrives.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
